Вакцина против вируса клещевого энцефалита на основе европейского прототипного штамма

03.11.2011

Литература

  1. Lindquist L, Vapalahti 0. Tick-borne encephalitis // Lancet. 2008. V. 371. P. 1861 - 1871.
  2. Suss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines // Vaccine. 2003. V. 21 (Suppl. 1). P. 19 - 35.
  3. Barrett RN., Plotkin S.A., Ehrllch H.J. Tick-borne encephalitis virus vaccines / In: Plotkin S.A., Orenstein W.A., Offit PA., eds. Vaccines, 5th ed. - Philadelphia, PA: Saunders Elsevier, 2008. P. 841 - 856.
  4. IVIansfleld K.L, Johnson N., Phlpps LP et al. Tick-borne encephalitis virus: a review of an emerging zoonosis // J. Gen. Virol. 2009. V. 90. P. 1781 - 1794.
  5. Suss J. Tick-borne encephalitis in Europe and beyond: the epidemiological situation as of 2007 // Euro. Survelll. 2008. V. 13 (26). Pii = 18916.
  6. Gubler D.J., Kuno G., Markoff L Flaviviruses / In: Knipe D.M., Howley RIVI. (eds.). Fields Virology, 5th ed. - Philadelphia: LIpplncott Williams aWilkins, 2007. R 1153 - 1252.
  7. Jaaskelainen A.E., Sironen Т., Murueva G.B. et al. Tick-borne encephalitis virus in ticks In Finland, Russian Karelia, and Buryatia // J. Gen. Virol. 2010. V. 91. R 2706 - 2712.
  8. Jaaskelainen A.E., Tikkakoski Т., Uzcategui N.Y. et al. Siberian subtype tickborne encephalitis virus, Finland // Emerg. Infect. DIs. 2006. V. 12. R 1568 - 1571.
  9. Chiba N., Osada IVI., Komoro K. et al. Protection against tick-borne encephalitis virus isolated In Japan by active and passive immunization //Vaccine. 1999. V. 17. R 1532 - 1539.
  10. Hayasaka D., Goto A., Yoshii K. et al. Evaluation of European tick-borne encephalitis virus vaccine against recent Siberian and Far-Eastern subtype strains // Vaccine. 2001 V. 19. R 4774 - 4779.
  11. Klockmann U., Krivanec K., Stephenson J.R., Hilfenhaus J. Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine // Vaccine. 1991. V. 9. R 210 - 212.
  12. Leonova G.N., Ternovoi V.A., Pavlenko E.V. et al. Evaluation of vaccine Encepur Adult for Induction of human neutralizing antibodies against recent Far-Eastern subtype strains of tick-borne encephalitis virus // Vaccine. 2007. V. 25. R 895 - 901.
  13. IS.Orlinger K.K., Holzer G.W., Schwaiger J. et al. An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system // Vaccine. 2010. V. 28. R 3318 - 3324.
  14. Ehrllch H.J., Muller M., Oh H.M. et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture // N. Engl. J. Med. 2008. V 358. R 2573 - 2584.
  15. Loew-Baselli A. Immunogenicity and safety of FSIVIE-lmmun 0.5 ml using a rapid immunization schedule // Int. J. Med. Microbiol. 2006. V. 296. R 213, 214.
  16. Lee E., Stocks C.E., Amberg S.M. et al. Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of slg-nalase cleavage in vitro is lethal for virus production // J. Virol. 2000. V. 74. R 24 - 32.
  17. Lobigs М., Lee E. Inefficient signalase cleavage promotes efficient nucleocapsid Incorporation into budding flavivirus membranes // J. Virol. 2004. V. 78. P. 178 - 186.
  18. Stocks C.E., Lobigs M. Signal peptidase cleavage at the flavivirus C-prlVI junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prIVI // J. Virol. 1998. V 72. R 2141 - 2149.
  19. Planltzer C.R., Modrof J., Kreil T.R. West Nile virus neutralization by US plasma-derived immunoglobulin products//J. Infect. Dis. 2007. V. 196. R 435 -440.
  20. Planltzer C.B., Modrof J., Yu M.Y., Kreil T.R. West Nile virus infection in plasma of blood and plasma donors. United States // Emerg. Infect. Dis. 2009. V 15. R 1668 - 1670.
  21. Seidel M.G., Grohmann E., Sadeghi K. et al. Vaccination against tick-borne encephalitis virus tests specific IgG production ability In patients under immunoglobulin substitution therapy // Vaccine. 2010. V. 28. R 6621 - 6626.
  22. Calistri R, Giovannini A., Hubaiek Z. et al. Epidemiology of West Nile in Europe and in the Mediterranean basin // Open Virol. J. 2010. V. 4. R 29 - 37.
  23. Rabel RO., Planltzer C.B., Farcet M.R. et al. Increasing West Nile Virus antibody titres in central European plasma donors from 2006 to 2010 // Euro. Surveii. 2011. V 16 (10):Pii = 19812.
  24. Csango RA., Blakstad E., Kirtz G.C. et al. Tick-borne encephalitis in southern Nonway// Emerg. Infect. Dis. 2004. V 10. R 533, 534.
  25. Heinz F.X., Holzmann H., EssI A., Kundi M. Field effectiveness of vaccination against tick-borne encephalitis // Vaccine. 2007. V. 25. R 7559 - 7567.
  26. Ben-Nathan D., Lustig S., Tarn G. et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice // J. Infect. Dis. 2003. V 188. R 5 - 12.
  27. Diamond M.S., Shrestha В., Marri A. et al. В cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus // J. Virol. 2003. V. 77. R 2578 - 2586.
  28. Engle M.J., Diamond M.S. Antibody prophylaxis and therapy against West Nile virus Infection in wild-type and immunodeficient mice // J. Virol. 2003. V 77. R 12941 - 12949.
  29. Kreil T.R., Burger I., Bachmann M. et al. Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages // Clin. Exp. Immunol. 1997. V 110. R 358 - 361.
  30. Kreil T.R., EibI M.M. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model //J. Virol. 1997. V. 71. R 2921 - 2927.
  31. Kreil TR., Maier E., FraissS., EibI M.M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral Immunity to a nonstructural virus protein //J. Virol. 1998. V 72. R 3076 - 3081.
  32. Tesh R.B., Arroyo J., Travassos da Rosa A.R et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model // Emerg. Infect. Dis. 2002. V. 8. R 1392 - 1397.
  33. Chambers TJ., Nestorowicz A., Mason RW., Rice CM. Yellow fever / Japanese encephalitis chimeric viruses: construction and biological properties //J. Virol. 1999. V 73. R 3095 - 3101.
  34. Lai C.I., Monath TR Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis // Adv. Virus Res. 2003. V. 61. R 469 - 509.
  35. Pletnev A.G., Bray M., Muggins J., Lai CJ. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses // Proc. Natl. Acad. Sol. USA. 1992. V 89. R 10532 - 10536.
  36. Johnson B.W., Kosoy 0., Hunsperger E. et al. Evaluation of chimeric Japanese encephalitis and dengue viruses for use In diagnostic plaque reduction neutralization tests // Clin. Vaccine Immunol. 2009. V 16. R1052 - 1059.
  37. Komar N., Langevin S., Monath T.R Use of a surrogate chimeric virus to detect West Nile virus-neutralizing antibodies in avian and equine sera // Clin. Vaccine Immunol. 2009. V 16. R 134,135.
  38. Pugachev K.V., Guirakhoo R, Mitchell F. etal. Construction of yellow fever/ St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool //Am. J. Trop. Med. Hyg. 2004. V 71. R 639 - 645.
  39. Barrett RN., Mundt W., Kistner 0., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. // Vaccines. 2009. V 8. R 607 - 618.
  40. Kistner C, Barrett RN., Mundt W. et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine // Vaccine. 1998. V. 16. R 960 - 968.
  41. Montagnon B.J., Fanget В., Nicolas AJ. The large-scale cultivation of Vero cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine // Dev. Biol. Stand. 1981. V 47. R 55 - 64.